

Monitoring the behaviour of 4-ketocyclophosphamide versus cyclophosphamide during capillary gas chromatography by mass spectrometry

Citation for published version (APA):

Bruijn, de, E. A., Oosterom, van, A. T., Leclercq, P. A., Haan, de, J. W., Ven, van de, L. J. M., & Tjaden, U. R. (1987). Monitoring the behaviour of 4-ketocyclophosphamide versus cyclophosphamide during capillary gas chromatography by mass spectrometry. *Biomedical & Environmental Mass Spectrometry*, 14(11), 643-647. <https://doi.org/10.1002/bms.1200141113>

DOI:

[10.1002/bms.1200141113](https://doi.org/10.1002/bms.1200141113)

Document status and date:

Published: 01/01/1987

Document Version:

Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.tue.nl/taverne

Take down policy

If you believe that this document breaches copyright please contact us at:

openaccess@tue.nl

providing details and we will investigate your claim.

Monitoring the Behaviour of 4-Ketocyclophosphamide *versus* Cyclophosphamide during Capillary Gas Chromatography by Mass Spectrometry

E. A. de Bruijn† and A. T. van Oosterom

Leiden University Medical Centre, Department of Clinical Oncology, Sylvius Laboratories, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands

P. A. Leclercq, J. W. de Haan and L. J. M. van de Ven

Eindhoven University of Technology, Laboratory of Instrumental Analysis, Department of Chemical Engineering, PO Box 513, 5600 MB Eindhoven, The Netherlands

U. R. Tjaden

Center for Bio-Pharmaceutical Sciences, Division of Analytical Chemistry, PO Box 9502, 2300 RA Leiden, The Netherlands

Capillary Gas Chromatography (CGC) is capable of determining underivatized cyclophosphamide (CPA) using SCOT OV 275 columns. Then CPA is subjected to *in situ* degradation resulting in formation of a cyclization product which can be determined selectively in biological fluids. In routine bioanalysis however cyclization products of CPA metabolites might interfere, e.g. 4-keto CPA. In the present study possible formation of cyclization products of 4-keto CPA similar to CPA was monitored by Mass Spectrometry. Cyclization of 4-keto CPA *in situ* was demonstrated to occur, resulting in a product similar to that of CPA. Both cyclization products could be determined selectively and it appeared that *in situ* cyclization of 4-keto CPA was negligible (<5%), probably owing to extra stabilization of the CPA metabolite by keto-enol tautomerism as has been demonstrated by NMR.

INTRODUCTION

Cyclophosphamide (CPA) (Fig. 1; 2-(bis-2-chloroethyl-amino)-tetrahydro-2H-1,3,2-oxazophosphorin-2-oxide) is a drug frequently used in cancer chemotherapy and as an immunosuppressant.^{1,2} CPA is metabolically activated *in vivo* by the cytochrome P₄₅₀ system to form 4-hydroxycyclophosphamide (4-OHCPA), iminocyclophosphamide (i-CPA), aldophosphamide (A-CPA), alcohosphamide (a-CPA) and *N*-dechloroethylcyclophosphamide (*N*-dClEt-CPA). Subsequent metabolism results in 4-ketocyclophosphamide (4-kCPA), chloroacetaldehyde, carboxyphosphamide (CPE), phosphoramidate mustard (PM), acrolein, hydracrylic acid, nor-HN₂, 3-(2-chloroethyl)-1,3-oxazolidin-2-one and *N*-2-chloroethylaziridine (Fig. 1).

4-OHCPA is believed by most investigators of the mechanisms of action of CPA to be the primary extracellular mediator of antitumour activity.³⁻⁵ Recently an important role for i-CPA has been demonstrated.⁶ Pharmacokinetics and metabolism of CPA have been found to vary widely;^{7,8} measurements of CPA and metabolites might be important in optimization of treatments with the alkylating agent.^{9,10} Sensitive and selective assays are required then; to date methods of analysis include radioactivity measurements of ¹⁴C-labelled CPA,¹¹ mass spectrometry,¹² gas chromatography/mass spectrometry (GC/MS),^{13,14} gas-liquid chromatography with and without derivatization of CPA,¹⁵⁻¹⁹ high performance liquid chromatography (HPLC)²⁰ and HPLC/field

desorption mass spectrometry.²¹ GC is the most widely used technique in clinical pharmacological studies, both with and without derivatization. Introduction of unchanged CPA into GC results in a derivative as depicted in Fig. 2; conditions for the reaction can be optimized in such a way that CPA can be determined in body fluids of CPA-treated patients properly without derivatization.^{13,18,19}

The selectivity of the assays with respect to other drugs regularly combined with CPA has been demonstrated. Taking metabolites of CPA into account, however, products like the 'on-column' product of CPA, the fundamental of the assay, might be formed and hinder selective analysis of CPA. Introduction of metabolites of CPA in capillary GC assays as described earlier by us¹⁹ revealed that only 4-kCPA might interfere. Injection of 4-kCPA in a gas chromatographic system consisting of SCOT OV-275 capillary columns and electron capture detection resulted in two peaks if 4-kCPA solutions were prepared just before introduction into the analytical system (Fig. 3). The peaks were thought to be related to unchanged 4-kCPA and an 'on-column' product as presented in Fig. 4.

Besides formation of 'on-column' products, another point needs further investigation: the peak shape of peak 2, which was considerably aberrant of peaks with comparable retention times in SCOT OV 275 capillary columns under similar conditions.¹⁹

The data of the present investigations place particular emphasis on the behaviour of 4-kCPA during elution on SCOT OV-275 columns and implications for the selectivity of CPA analysis by capillary GC without derivatization.

† Author to whom correspondence should be addressed.




Figure 1. Metabolism of cyclophosphamide.

EXPERIMENTAL

Chemicals

CPA and metabolites of interest were kindly donated by ASTA-Werke (Bielefeld, FRG). Solvents used were of analytical grade and obtained from Baker (Deventer, The Netherlands) and Merck (Darmstadt, FRG). Freshly prepared ethyl acetate samples were introduced into the column at 250 °C (falling needle) and 83 °C (on column).

Columns

A fused silica WCOT CP SIL 5CB column (25 × 0.21 mm i.d.) was used for elution of 4-kCPA.

Mass Spectrometry

A Finnigan model 4000 quadrupole mass spectrometer (Finnigan, Sunnyvale, California, USA) was used both in the electron impact (EI) and chemical ionization (CI) mode. Mass spectral data were obtained under the following conditions: ionizing electron energy, 70 eV;

electron current, 0.30 mA; scan time, 1 s; source temperature, 250 °C (EI) and 200 °C (CI). For the CI mode, NH₃ reactant gas was introduced via the make-up gas line. The ion source was maintained at 0.15 Torr gauge




Figure 3. A chromatogram of 4-kCPA (1) and an 'on-column' product (2) and compounds not related to CPA and/or 4-kCPA. 5-FUraH₂: 5,6 dihydro-5-fluorouracil; 5-FUra: 5-fluorouracil; 5-CUra: 5-chlorouracil.




Figure 2. Cyclization process of CPA following injection on capillary GC.




Figure 4. Possible 'on-column' product of 4-kCPA.




Figure 5. Chromatographic profile of 4-kCPA following on-column injection at 83 °C. Temperature programme: 83 °C to 225 °C (1.5 deg. C/s).

reading. The WCOT fused silica column was operated isothermally in MS experiments.

RESULTS AND DISCUSSION

A chromatogram obtained upon on-column injection at 83 °C using a fused silica WCOT CP SIL-5 column followed by programmed temperature increase from 83 °C to 225 °C at 1.5 deg./s is presented in Fig. 5. Two peaks can be noted, with retention times (t_R) of 6.1 and 8.3 min, respectively. The peak area of peak 1 was less than 5% of peak 2. A slightly raised baseline between peaks 1 and 2 could be distinguished, indicating that on-column reactions as well as reactions in the injection system of 4-kCPA take place.

When a total ion current chromatogram of 4-kCPA was recorded using split injection at 250 °C under otherwise similar conditions, again two peaks were observed, with $t_R = 4.5$ min and $t_R = 7.0$ min (Fig. 6). The peak area of peak 1 was 8% of peak 2. Furthermore, asymmetric peaks were observed in contrast to peaks of Fig. 5.

EI mass spectral fragmentation

The EI mass spectrum of peak 1 is given in Fig. 7(a). Fragment ions m/z 189, 161 and 117 were produced. The ions are degradation products of the M^+ ion at




Figure 6. Total ion current chromatogram of 4-kCPA using solid injection at 250 °C. A fused silica WCOT CP Sil-5 column (25 × 0.21 mm i.d.) at 230 °C was used.

m/z 238, which was not observed owing to rapid degradation to the ion at m/z 189 by loss of CH_2Cl . The EI mass spectrum of peak 2 is given in Fig. 7(b). Ions at m/z 225, 189, 163, 161, 134, 117 and 92 were formed. The fragmentation processes, together with their percentages as obtained from EI mass spectrometry, of peaks 1 and 2 are presented in Fig. 8.

CI mass spectral fragmentation

The CI mass spectrum of peak 1 is given in Fig. 9(a). Two ions were formed: MH^+ (m/z 239) and MNH_4^+ (m/z 256). The CI mass spectrum of peak 2 is presented in Fig. 9(b). MH^+ (m/z 275) and MNH_4^+ (m/z 292) were formed, as well as the fragment ion $MH^+ - HCl$ (m/z 239). Pathways of degradation during capillary GC and CI mass spectrometry with percentages of products formed are depicted in Fig. 10.

As Figs 8 and 10 demonstrate, peak 1 is associated with a cyclization product of 4-kCPA produced during capillary chromatography, while selectivity towards unchanged 4-kCPA is sufficient. The comparable cyclization product of CPA and unchanged CPA could be well separated from 4-kCPA and its 'on-column' product. Moreover, the amount of the 'on-column' product of CPA is negligible when capillary GC with a temperature programme is used. Keto-enol tautomerism of 4-kCPA was thought to be related to the relatively low amounts of 'on-column' products of 4-kCPA as well as some forms of peak asymmetry. This possibility was




Figure 7. EI mass spectra of (a) peak 1 and (b) peak 2, as presented in Fig. 6.




Figure 8. Fragmentation processes of EI mass spectrometry of 4-kCPA.




Figure 9. CI mass spectra of (a) peak 1 and (b) peak 2, as presented in Fig. 6.




Figure 10. Fragmentation processes of CI mass spectrometry of 4-kCPA.




Figure 11. Thermal desorption of 4-kCPA.




Figure 12. Thermal desorption mass spectra of (a) peak A and (b) peak B, as presented in Fig. 11.




Figure 13. Thermal desorption fragmentation processes of 4-kCPA.

further investigated by thermal desorption mass spectrometry and nuclear magnetic resonance (NMR). Measurements by thermal desorption (EI) mass spectrometry with a fast temperature programme (0.15 A/s) and NMR confirmed the existence of keto-enol tautomerism at temperatures below 150 °C, as can be seen in Figs 11, 12, 13 and 14. Both peaks (A and B), as depicted in Fig. 11, show identical mass spectra (Fig. 12(a) and (b)).

Figure 13 shows pathways of degradation during thermal desorption mass spectrometry, together with percentages of formed products. NMR data of 4-kCPA solutions in CDCl₃ finally give confirmation of the existence of keto-enol tautomerism as an OH signal at 1.65 ppm.

Tautomerism might also be responsible for peak asymmetry. However, peak broadening can increase to such an extent¹⁹ that absorption of one or both of the compounds of the tautomeric mixture cannot be excluded. Implications of the keto-enol tautomerism of 4-kCPA with respect to *in vivo* metabolism of 4-kCPA are currently being investigated; indications for reversible CPA metabolism have now been found in which the tautomerism might play a key role.²²




Figure 14. NMR spectrum of 4-kCPA in CDCl₃.

CONCLUSIONS

The experimental evidence presented here strongly supports the selectivity of capillary GC of underivatized CPA and 4-kCPA with respect to their 'on-column' products as well as unchanged compounds. A keto-enol tautomerism of 4-kCPA has been demonstrated at temperatures below 150 °C; the tautomerism is assumed to

be a determining factor for the behaviour of 4-kCPA during capillary GC.

Acknowledgements

The authors are grateful to ASTA-Werke, de 'Saal van Zwanenberg Stichting' and 'Linea Science'.

REFERENCES

1. H. Arnold and F. Boerseaux, *Angew. Chem.* **70**, 539 (1958).
2. J. Holland and E. Frei, III, *Cancer Medicine*, Lea & Febiger, Philadelphia (1973).
3. B. E. Domeyer and N. E. Sladek, *Cancer Res.* **40**, 174 (1980).
4. N. Brock and J. J. Hohorst, *Z. Krebsforsch.* **88**, 185 (1977).
5. P. J. Cox, B. J. Phillips and P. Thomas, *Cancer Res.* **35**, 3755 (1975).
6. C. Fenselau, M.-N. Kan and S. S. Rau, *Cancer Res.* **37**, 3738 (1977).
7. P. H. Th. J. Slee, E. A. de Bruijn, O. M. J. Driessen, J. Hermans and A. T. van Oosterom, *Anticancer Res.* **3**, 269 (1983).
8. H. Mouridsen, O. Farmer and L. Skovsted, *Acta Pharmacol. Toxicol.* **35**, 98 (1974).
9. M. N. Mruzek and I. C. Shaw, *Biomed. Mass. Spectrom.* **11**, 360 (1984).
10. L. B. Grochow and M. Colvin, *Clin. Pharmacokin.* **4**, 380 (1979).
11. J. Cohen, J. Jao and W. Jusko, *Br. J. Pharmacol.* **43**, 677 (1971).
12. U. Bahr, H. R. Schulten, O. R. Hammes and F. Aerts, *Clin. Chim. Acta* **103**, 183 (1980).
13. C. Pantarotto, A. Martini, G. Belvedere, M. G. Donelli and A. Frigerid, *Cancer Treat. Rep.* **60**, 493 (1976).
14. C. Lartigue-Mattei, J. L. Chabard, C. Touzet, H. Bargnoux, J. Petit and J. A. Berger, *J. Chromatogr.* **310**, 407 (1984).
15. F. D. Juma, H. J. Rogers, J. R. Trouce and I. D. Bradbrook, *Cancer Chem. Pharmacol.* **1**, 229 (1978).
16. T. Fachinetti, M. D. d'Incalci, G. Martinelli, L. Cantoni, G. Belvedere and M. Salmona, *J. Chromatogr.* **145**, 315 (1978).
17. B. Whiting, S. H. K. Miller and B. Caddy, *Br. J. Clin. Pharmacol.* **6**, 373 (1978).
18. N. van den Bosch and D. de Vos, *J. Chromatogr.* **183**, 49 (1980).
19. E. A. de Bruijn, U. R. Tjaden, A. T. van Oosterom, P. Leeflang and P. A. Leclercq, *J. Chromatogr.* **279**, 603 (1983).
20. R. W. Hardy, C. Erlichman and S. J. Soldin, *Ther. Drug Mon.* **6**, 313 (1984).
21. M. Przybylski, *Arzneim.-Forsch./Drug Res.* **32**, 995 (1982).
22. Data presented at the Pittsburg Conference of Analytical Chemistry and Spectrometry, Atlantic City (1986). In press.